Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa

References

• US Renal Data System. USRDS 2000 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000
   Google Scholar
• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504–10
   Google Scholar
• McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501–10
   PubMed Web of Science ®Google Scholar
• Abu-Alfa AK. CKD Series. Evaluation and treatment of anemia in chronic kidney disease. Hospital Physician 2003;46:31–8
   Google Scholar
• Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803–12
   PubMed Web of Science ®Google Scholar
• Hsu CY, Bates DW, Kuperman GJ, et al. Relationship between hematocrit and renal function in men and women. Kidney Int 2001;59:725–31
   PubMed Web of Science ®Google Scholar
• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125–34
   PubMed Web of Science ®Google Scholar
• Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2002;162:1401–8
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S1–S146
   Google Scholar
• Massimetti C, Pontillo D, Feriozzi S, et al. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 1998;16:317–24
   PubMed Web of Science ®Google Scholar
• Silberberg J, Racine N, Barre P, et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1–4
   PubMed Web of Science ®Google Scholar
• Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992;61:21–5
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548–54
   PubMed Web of Science ®Google Scholar
• Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108–14
   PubMed Web of Science ®Google Scholar
• Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and renal function in predialytic uremic patients. Nephron 1992;60:390–6
   PubMed Web of Science ®Google Scholar
• Holland D, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000;15:650–8
   PubMed Web of Science ®Google Scholar
• Ortho Biotech Products, L.P. Procrit® (epoetin alfa) full prescribing information. Available at http://www.procritline.com/common/prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf [accessed June 29, 2007]
   Google Scholar
• Amgen Inc. Aranesp® (darbepoetin alfa) for injection. Available at http://www.aranesp.com/pdf/aranesp_PI.pdf [accessed June 29, 2007]
   Google Scholar
• Singh AK, Szczech L, Tang K, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med 2006;355:2085–98
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 2006;355:2071–84
   Google Scholar
• Cotter D, Thamer M, Narasimhan, et al. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Aff (Millwood). 2006;25:1249–59
   PubMed Web of Science ®Google Scholar
• Suranyi MG, Lindberg JS, Navaroo J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23:106–11
   PubMed Web of Science ®Google Scholar
• Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453–60
   PubMed Web of Science ®Google Scholar
• Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327–34
   PubMed Web of Science ®Google Scholar
• Papatheofanis F, McKenzie RS, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006;22:837–42
   PubMed Web of Science ®Google Scholar
• Papatheofanis F, McKenzie RS, Mody S, et al. Hematologic outcomes and dosing patterns of erythropoietic agents in anemic predialysis chronic kidney disease (pCKD) patients from an observational study. J Am Soc Nephrol 2005;16:547A [abstract F-PO969. Poster presented at the 38th Annual Renal Week Meeting of the American Society of Nephrology (ASN)]; 2005 November 8–13; Philadelphia, PA
   Google Scholar
• Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381–95
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47
   PubMed Web of Science ®Google Scholar
• Medi-Span Master Drug Database. Available at: http://www.medispan.com/Products/index.aspx?id=1 [accessed October 24, 2006]
   Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):3–13
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–5
   PubMed Web of Science ®Google Scholar
• Mody S, Padmanabhan V, McKenzie RS, et al. Epoetin alfa and darbepoetin alfa dosing patterns in pre-dialysis chronic kidney disease patients. Value Health 2006;9:A96 [abstract PUK5]
   Google Scholar
• Anon. 2003 Medicare hospital outpatient prospective payment system final rule. Federal Register 2002;67:66757–9
   Google Scholar
• Federal Register: June 25, 2004. Department of Health and Human Services Centers for Medicare & Medicaid Services [CMS-9022-N]. From the Federal Register found on www.cms.gov (epoetin alfa search) [from November 15, 2004]: http://www.cms.hhs.gov/providerupdate/regs/cms1427fc_3.pdf
   Google Scholar
• Lefebvre P, Mody SH, McKenzie RS, et al. Epoetin alfa and darbepoetin alfa dosing patterns and drug costs in patients with pre-dialysis chronic kidney disease. Am J Kid Dis 2006;47(4): A39 [abstract 84]. Poster presented at the Spring Clinical Meetings of the National Kidney Foundation (NKF); 2006 April 19–23; Chicago, IL
   Google Scholar
• McLaughlin T, Mody SH, McKenzie RS, et al. Dosing patterns and associated costs of erythropoietic agents in a nationwide sample of anemic patients with pre-dialysis chronic kidney disease. J Manag Care Pharm 2006;12(2):182 [poster presented at the 18th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy (AMCP)]; 2006 April 5–8; Seattle, Washington
   Google Scholar